Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.The Recursion Pharmaceuticals Analyst: Analyst Gil Blum maintained a Buy rating and price target of $11.The Recursion Pharmaceuticals Thesis: The company's May update, during which it will provide insights into its pipeline and financial guidance, remains "the primary near-term driver," Blum said in the note.Check out other analyst stock ratings.Rec ...